Who owns IOVANCE BIOTHERAPEUTICS, INC. (IOVA)? Elite investor 13F holders
2 tracked elite investors reported holding IOVANCE BIOTHERAPEUTICS, INC as of 2026-06-30, including D.E. Shaw, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | IOVANCE BIOTHERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 8915437.00 USD | 2143134.000000 | Shares | reduce | Original filing |
| Tudor Investment | IOVANCE BIOTHERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1222994.00 USD | 293989.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.